VECTURA GROUP (VEC.L, LSE, LSE:VEC)
VEC Share PerformanceMore
|52 week high||182.00 28/05/15|
|52 week low||113.25 16/10/14|
|52 week change||49.00 (37.40%)|
|4 week volume||17,940,183 02/05/15|
Latest News« previous» nextMore
20/05/2015 - 09:24 StockMarketWire
Vectura Group has issued its preliminary results for the year ended 31 March 2015. It described the year as transformation...
20/05/2015 - 07:00 RNS
RNS Number: 7122N Vectura Group plc 20 May 2015 Vectura Group plc - Preliminary Results Transformational Year - Maiden Profit Chippenham, UK - 20 May 2015: Vectura Group plc (LSE: VEC) ("Vectura"), which specialises in the development of products for the treatment of airways-related diseases , announces today its preliminary results for the year ended...
18/05/2015 - 10:36 RNS
RNS Number: 4834N Vectura Group plc 18 May 2015 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Vectura Group PLC 2 Reason for the notification (please tick th...
01/05/2015 - 10:22 StockMarketWire
Vectura Group has confirmed that the information released today by The Medicines Company announcing that the U.S. F...
01/05/2015 - 10:17 RNS
RNS Number: 0033M Vectura Group plc 01 May 2015 Vectura Group plc US FDA approval of RAPLIXA (fibrin sealant) Chippenham, UK - 1 May 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), confirms the information released today by The Medicines Company (NASDAQ:MDCO) announcing that the U.S. Food and Drug Administration (FDA...
01/05/2015 - 07:00 RNS
RNS Number: 9242L Vectura Group plc 01 May 2015 Vectura Group plc (the "Company") VOTING RIGHTS AND CAPITAL Chippenham, UK, 1 May 2015: In accordance with the Financial Conduct Authority's Transparency Directive, Transitional Provision6, Vectura Group plc (LSE: VEC) ("the Company") wishes to notify the market of the following: The Compa...
20/04/2015 - 15:21 Motley Fool
After a record-breaking 2014, 2015 is shaping up to be another momentous year for biotech. During the first few months o...
17/04/2015 - 14:45 StockMarketWire
Dr Christopher Blackwell, Chief Executive Officer, exercised 18,987 shares in the company on the 16th April 2015 at a price...
|Dividend yield||0 %|
Latest discussion posts More
Codes & Symbols
|Symbols||VEC, LSE:VEC, VEC.L, VEC:LN, LON:VEC, XLON:VEC|